Core Viewpoint - The company is actively pursuing several strategic initiatives that are expected to enhance its market position and profitability, including the introduction of new products and the divestiture of real estate assets [1] Group 1: Product Development and Market Potential - The company is on the verge of having Jin Nakan (金纳单抗) included in breakthrough therapy designation [1] - Anwo Gao (安沃高新) is set to commence production, with an expected annual output value of 3 billion [1] - The market for insoles and weight loss drugs is substantial, which is anticipated to generate significant profits [1] - The introduction of methylphenidate hydrochloride (盐酸右哌甲酯) is expected to tap into a large market space [1] - Jin Tuoxizhu (金妥昔单抗) and Jin Tuolizhu (金妥利珠单抗) are projected to be billion-dollar products [1] Group 2: Strategic Initiatives and Financial Management - The company is actively advancing its real estate divestiture strategy [1] - The company aims to balance expenditure to maintain stable profits [1] - The growth hormone business currently faces no competition in the market [1]

Group 1 - The company has established a partnership with Tianlu Technology to create a new AI pharmaceutical company, Saiwu Jianfei, to enhance collaboration and expand related business [1] - The management highlighted that Meishiya possesses significant advantages in technology, clinical needs, and commercialization capabilities, with minimal competition in the short term as the only nano-formulation in a blue ocean market [1] - The company is actively promoting the approval process for its products, with the powder formulation expected to be approved this year, while similar products from competitors are still in clinical stages [2] Group 2 - The company has implemented a series of compliance management systems for recruitment and assessment over its 30-year development, addressing concerns about hiring practices and employee experiences [3] - The company plans to optimize a small portion of its workforce while ensuring the stability of its core team, aiming to enhance efficiency and reduce costs in alignment with its strategic planning [3] - The company is committed to responding to industry trends by increasing innovation investments and introducing cutting-edge pharmaceutical products and technologies across various sectors [2]